Hospital Arnau De Vilanova De Valencia — Clinical Trial Site

89 Registered trials

29 Currently recruiting

Organisation

Hospital Arnau De Vilanova De Valencia

Location

Valencia, Spain

Identifier

ORG-100041230

Address

Calle De San Clemente 12, 46015, Spain

Departments

-
#2356: Servicio de dermatología
1407:Dermatología
6508: Dermatología
7001: Oncología Médica
7005: Hematología
9758; Dermatología
Allergology
Cardiology
Departamento de Oncología
Dermatology
ESP002: Oncología Médica
Gastroenterology and Hepatology
Hematología
Hematology
Intensive Care Unit
Medical Oncology
Medicine
NEUMOLOGÍA
Neumology
Oncología Médica
Oncology
Oncology department
Ophtalmology
Ophthalmology
Pediatria
Pneumology
Pulmonology
Servicio de Cardiologia
Servicio de Dermatología
Servicio de Hematología
Servicio de Hematología y Hemoterapia
Servicio de Medicina Interna
Servicio de Neumología
Servicio de Oncología
Thoracic Oncology
Unidad de Ensayos Clínicos

Clinical trials at this site (89)

Search interface

THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICA… Ended

2023-507304-32-00 Chronic Obstructive Pulmonary Disease 6 2024-02-09
A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HE… Ended

2023-503251-10-00 Metastatic Breast Cancer or Advanced Non-Small Cell Lun 4 2023-10-10
PREOPERATIVE WINDOW OF OPPORTUNITY STUDY WITH GIREDESTRANT (GDC-9545) OR TAMOXIFEN IN PREMENOPAUSAL WOMEN WITH ER[+]/HER2[-] & KI67≥10% EARL… Ended

2023-503565-36-00 ER[+]/HER2[-] & Ki67≥10% early breast cancer (EBC) 4 2023-07-19
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients wi… Ended

2022-501601-12-00 Diffuse large B-cell Lymphoma 4 2023-05-22
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended

2022-501538-44-00 Atopic Dermatitis 5 2023-04-25
A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration Ended

2024-512879-13-00 Neovascular age-related macular degeneration (wet AMD) 5 2021-09-23
A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended

2023-505203-23-01 Severe asthma with an eosinophilic phenotype 5 2021-07-26
A phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously tr… Ended

2024-514611-98-00 PIK3CA mutated HER2+ advanced or relapsed breast cancer 5 2021-07-20
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-510175-60-00 Chronic obstructive pulmonary disease (COPD) and Chron 5 2021-06-16
Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended

2023-510230-84-00 Severe asthma with an eosinophilic phenotype 5 2021-05-28
A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab… Ended

2023-507317-10-00 Locally advanced, unresectable, or metastatic non small 5 2021-05-10
A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended

2023-509591-42-00 HR-positive/HER2-negative breast cancer 4 2021-05-04
A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym… Ended

2023-507271-21-00 Follicular Lymphoma 5 2017-04-11
A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and … Ended

2023-504034-22-00 Chronic Lymphocytic Leukemia (CLL) 5 2014-12-18
A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended

2022-501353-37-00 Reversal of anticoagulation effect in patients on a FXa 5
A Study of Valemetostat Tosylate Plus Pembrolizumab versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations Ended

2024-519671-26-00 Advanced or Metastatic Non-Small Cell Lung Cancer 9
A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LIN… Ended

2025-521489-80-00 PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER 4